泛素-蛋白酶体通路是生物体内进行蛋白质选择性降解的重要途径之一,它参与了细胞内许多重要的生理生化过程。蛋白酶体抑制剂可阻断大量调节蛋白的降解,引起细胞内信号系统的紊乱和超负荷,导致细胞生长的抑制,最终使肿瘤进展过程延缓甚至停滞。硼替佐米作为一种蛋白酶体抑制剂,能抑制多发性骨髓瘤细胞的生长及诱导肿瘤细胞的凋亡,同时对血液系统其他恶性肿瘤具有显著作用。本文就蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究作一综述。 The ubiquitin-proteasome pathway is one of the important pathways for protein selective degradation in the organism. It participates in many important physiological and biochemical processes in the cell. Proteasome inhibitors can block a large number of regulatory protein degradation, causing intracellular signaling system disorders and overload, leading to inhibition of cell growth, and ultimately the process of tumor progression delay or even stagnation. Bortezomib, as a proteasome inhibitor, can inhibit the growth of multiple myeloma cells and induce the apoptosis of tumor cells, and has a significant effect on other hematological malignancies. This review summarizes the research on the treatment of hematological malignancies by proteasome inhibitor bortezomib.